DESTINY-Breast03 Phase 3 Study Results
Progression-Free Survival Probability (%)
PFS and OS in HR- (Exploratory Endpoints)
100
60
40
A 5.6 mo
TPC
mPFS: 2.9 mo
PFS
Hazard ratio: 0.46
95% CI, 0.24-0.89
T-DXd
mPFS: 8.5 mo
Overall Survival Probability (%)
10
Daiichi-Sankyo
DESTINY-Breast04
100
OS
Hazard ratio: 0.48
95% CI, 0.24-0.95
60
60
40
40
20
20
TPC
MOS: 8.3 mo
T-DXd
MOS: 18.2 mo
A 9.9 mo
0
0
0123
6
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Months
01
2
3 4 5 6 7 8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Months
No. at Risk
T-DXD (n = 40): 40 39 33 29 28 25 21 20 19 18 13 13 11 11 10 8 7 5 5 4 4
TPC (n = 18): 18 17 11 7 6 4 3 3 2 2 2 2 2 2 1111110
4 4 3
1 0
No. at Risk
T-DXD (n = 40): 40 39 38 37 36 34 34 32 31 30 28 27 26 26 23 23 19 14 13 9
TPC (n = 18): 18 17 16 14 14 14 3 11 10 8 8 8 7 6 6 5 5 5 5 3 3
9
82
72
72
160
6 5 4 4
HR, hormone receptor; mOS, median overall survival; mPFS, median progression-free survival; OS, overall survival; PFS, progression-free survival; T-DXd, trastuzumab deruxtecan; TPC, treatment of physician's choice.
For efficacy in the hormone receptor-negative cohort, hormone receptor status is based on data from the electronic data capture corrected for misstratification.
ASCO 2022 #LBA3 Plenary Session
14View entire presentation